Atea reports Q4 net loss $44.9M, cash $301.8M; HCV Phase 3 topline mid-2026; HEV program mid-2026

Atea Pharmaceuticals, Inc.

Net loss $44.9M in Q4 2025 (EPS -$0.57) vs $33.5M loss in Q4 2024; full-year net loss $158.3M.
Cash and investments $301.8M at Dec 31, 2025, down from $454.7M a year ago.
R&D expense $47.8M in Q4, up from $25.7M YoY, driven by HCV Phase 3 spend including milestone to Merck.
Global Phase 3 HCV program: C-BEYOND (enrolled >880) topline mid-2026; C-FORWARD enrollment complete mid-2026, topline year-end 2026.
Expanded antiviral pipeline: HEV program with AT-587 expected to enter clinic mid-2026; presented in vitro data at CROI 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Atea Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.

Period: the fourth quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Atea Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-093961

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.